News
ENLV
0.5975
-1.35%
-0.0082
Enlivex Posts Massive H1 2026 Profit on Surging Digital Asset Holdings
TipRanks · 2d ago
Envilex Therapeutics GAAP EPS of $108.50
Seeking Alpha · 2d ago
12 Health Care Stocks Moving In Tuesday's Intraday Session
Benzinga · 5d ago
Enlivex Drops RAIN-Token Financing Deal, Halts Planned Private Placement
TipRanks · 5d ago
Weekly Report: what happened at ENLV last week (0914-0918)?
Weekly Report · 6d ago
12 Health Care Stocks Moving In Thursday's Intraday Session
Benzinga · 09/17 17:05
Weekly Report: what happened at ENLV last week (0907-0911)?
Weekly Report · 09/14 10:12
Weekly Report: what happened at ENLV last week (0831-0904)?
Weekly Report · 09/07 10:06
Enlivex Ltd. (ENLV) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
NASDAQ · 09/01 13:55
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Benzinga · 09/01 12:06
Weekly Report: what happened at ENLV last week (0824-0828)?
Weekly Report · 08/31 10:13
12 Health Care Stocks Moving In Thursday's After-Market Session
Benzinga · 08/27 21:07
Weekly Report: what happened at ENLV last week (0817-0821)?
Weekly Report · 08/24 10:13
12 Health Care Stocks Moving In Friday's After-Market Session
Benzinga · 08/21 21:06
Weekly Report: what happened at ENLV last week (0810-0814)?
Weekly Report · 08/17 10:14
Enlivex Restructures $19.2 Million Convertible Note With Lind, Easing Default Risk
TipRanks · 08/11 20:48
Weekly Report: what happened at ENLV last week (0803-0807)?
Weekly Report · 08/10 10:10
Enlivex Therapeutics registers to sell 10M ordinary shares for holders
TipRanks · 08/06 20:51
Enlivex Price Target Raised to $80.00/Share From $20.00 by HC Wainwright & Co.
Dow Jones · 08/03 10:39
Enlivex Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 08/03 10:39
More
Webull provides a variety of real-time ENLV stock news. You can receive the latest news about Enlivex Ltd through multiple platforms. This information may help you make smarter investment decisions.
About ENLV
Enlivex Ltd, formerly known as Enlivex Therapeutics Ltd, is an Israel-based clinical-stage macrophage reprogramming immunotherapy company developing Allocetra, an off-the-shelf cell therapy designed to restore macrophages to their homeostatic state. The Company focuses on diseases in which macrophages are pathologically reprogrammed, such as solid cancers, sepsis and COVID‑19, where non-homeostatic macrophages contribute significantly to disease severity. By re-establishing macrophage homeostasis, Allocetra has the potential to provide an immunotherapeutic mechanism of action for life-threatening indications defined as unmet medical needs, either as a stand‑alone therapy or in combination with other treatments.